Combination of Serum Albumin and Cholinesterase Levels as Prognostic Indicator in Patients ith Colorectal Cancer

Yamamoto, Manabu; Saito, Hiroaki; Uejima, Chihiro; Tanio, Akimitsu; Tada, Yoichiro; Matsunaga, Tomoyuki; Sakamoto, Teruhisa; Honjo, Soichiro; Ashida, Keigo; Fujiwara, Yoshiyuki

doi:10.21873/anticanres.13217

Cited by 38 publications

(41 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,63 Either elevated serum CRP level or low serum ALB level has been shown to be associated with poor survival in multiple types of cancer patients. 4,6,[23][24][25][26][27][28][29][30] Taken together with the prognostic role GPS and CAR for cancer patients, these evidences highlight the importance of serum CRP and ALB level in the prediction of survival for malignancies. Elevated CRP level or low ALB level might represent an inherent aggressive propensity of the cancers including neuroblastoma.…”

Section: Discussionmentioning

confidence: 82%

Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma

Chen

Liu

Feng

et al. 2020

CMAR

View full text Add to dashboard Cite

The prognostic significance of inflammation-based biomarkers for neuroblastoma (NB) has not been investigated before. The aim of this study was to evaluate the prognostic value of pre-treatment inflammation biomarkers in children patients with NB. Patients and Methods: Patients diagnosed with NB from 2008 to 2016 in our institution were enrolled in this study. The clinical data and survival outcomes were retrospectively reviewed. Inflammation biomarkers or scores including C-reactive protein (CRP), albumin (ALB), Glasgow Prognostic Score (GPS), modified Glasgow Prognostic Score (mGPS), high-sensitivity modified Glasgow Prognostic Score (Hs-mGPS), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and system inflammation index (SII) were tested in this study. Univariate and multivariate survival analyses were performed to assess the prognostic value of these inflammation indicators for overall survival (OS) of children with NB. Kaplan-Meier survival curves were also conducted. Results: A total of 70 children diagnosed with neuroblastoma were enrolled in this study. NLR, PLR, LMR and SII were found to be not predictive of OS for NB patients. However, CRP, ALB, GPS and CAR were significantly associated with OS of NB patients. Multivariate analysis adjusting for age, sex, histology, tumor size, tumor stage and metastasis revealed that ALB, CAR, GPS and Hs-mGPS were significantly associated with OS of NB patients. Receiver operating characteristic (ROC) curves and Akaike Information Criterion (AIC) analyses revealed that Hs-mGPS is superior to other inflammation biomarkers in predicting OS of NB patients. Subgroup survival analysis for immature NB patients revealed similar results. Conclusion: Hs-mGPS is an effective prognostic factor for OS of patients with NB and is promising to be used as a factor for risk stratification and an indicator for more aggressive therapy.

show abstract

Section: Discussionmentioning

confidence: 82%

Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma

Chen

Liu

Feng

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Hence, we further explored possible reasons. ChE is a common serum marker that reflects the nutritional status of patients [19]. It has been reported that low serum ChE levels are associated with liver damage, inflammation, and malnutrition [20].…”

Section: Discussionmentioning

confidence: 99%

Serum Cholinesterases, a Novel Marker of Clinical Activity in Inflammatory Bowel Disease: A Retrospective Case-Control Study

Shao

Yang

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

Background. The aim of our study was to investigate whether serum cholinesterase (ChE) levels were associated with inflammatory bowel disease (IBD). Materials and Methods. We conducted a retrospective case-control study to clarify the relationship between serum ChE levels and IBD that included 142 patients with ulcerative colitis (UC), 60 patients with Crohn’s disease (CD), and 264 healthy controls (HCs). We used ROC curves to evaluate the diagnostic value of serum ChE levels for IBD. Results. Substantially lower serum ChE levels were detected in patients with UC than in HCs (6376 U/L versus 8418 U/L, P<0.001) and in patients with CD than in HCs (5181 U/L versus 8418 U/L, P<0.001). Additionally, patients with CD displayed significantly lower serum ChE levels than patients with UC (5181 U/L versus 6376 U/L, P<0.01). We also found that there was a negative association between serum ChE levels and the Crohn’s Disease Activity Index (CDAI) score of patients with CD (P=0.011) and the Simple Clinical Colitis Activity Index (SCCAI) score of patients with UC (P=0.018). The area under the curve (AUC) for serum ChE for the diagnosis of IBD was 0.826, and the AUCs of serum ChE for the diagnosis of CD and UC were 0.890 and 0.800, respectively. Conclusions. Serum ChE levels have important clinical significance in the diagnosis and assessment of clinical activity in patients with IBD, and the cholinergic anti-inflammatory pathway may provide new ideas for targeted treatment of IBD.

show abstract

“…Malnutrition can lead to the decline of immune function in cancer patients, thus increasing the risk of postoperative complications and tumor progression. 21 Previous studies have reported that hypoalbuminemia is associated with disease progression and poor prognosis in patients with colon cancer, 22 pancreatic cancer, 23 non-small cell lung cancer, 24 ovarian cancer, 25 and GC. 26 Furthermore, this study shows that preoperative CEA is an independent prognostic factor of survival, consistent with previous studies.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of the Combination of CEA and Fibrinogen/Albumin Ratio in Resectable Gastric Cancer

Zhang

Ruan

Wang

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose: To investigate the prognostic value of combined serum carcinoembryonic antigen (CEA) levels and fibrinogen/albumin ratio (FAR) in patients with resectable gastric cancer (GC). Introduction: This retrospective study evaluated the CEA, fibrinogen, and albumin levels and other clinicopathological features of GC patients. The prognostic significance of these factors for overall survival (OS) was assessed using Kaplan-Meier curves and univariate and multivariate Cox proportional models. Patients and Methods: A total of 267 patients were included. The optimal cutoff values of CEA and FAR were 3.2 ng/mL and 0.086, respectively. Patients were stratified into three groups based on this cutoff value: CEA-FAR=0 (CEA <3.2 ng/mL and FAR <0.086), CEA-FAR=1 (CEA ≥3.2 ng/mL or FAR ≥0.086), and CEA-FAR=2 (CEA ≥3.2 ng/mL and FAR ≥0.086). Results: Higher CEA-FAR was strongly associated with age, tumor size, tumor invasion, lymph node status, and TNM stage (all P<0.05). The OS rates differed significantly between these 3 groups (88.9% vs 65.0% vs 46.9%, P<0.001). Multivariate analysis showed that CEA-FAR was an independent prognostic factor for OS (P<0.001). The area under the curve was larger for CEA-FAR than for either CEA or FAR alone (0.683, 0.644, and 0.669, respectively). Conclusion: Preoperative CEA-FAR could be a potential blood marker for predicting tumor progression and the prognosis of GC patients. Patients with a higher CEA-FAR should undergo extensive follow-up.

show abstract

Combination of Serum Albumin and Cholinesterase Levels as Prognostic Indicator in Patients ith Colorectal Cancer

Cited by 38 publications

References 24 publications

<p>Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma</p>

<p>Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma</p>

Serum Cholinesterases, a Novel Marker of Clinical Activity in Inflammatory Bowel Disease: A Retrospective Case-Control Study

<p>Prognostic Value of the Combination of CEA and Fibrinogen/Albumin Ratio in Resectable Gastric Cancer</p>

Contact Info

Product

Resources

About